Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme

This is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tecentriq), an FDA approved PD- L1 inhibitor drug, 840 mg IV, at the beginning and at the end of the two-week time period, concomitantly with FSRT. After this initial two weeks treatment the patients will undergo craniotomy and maximal safe resection as per normal care for a GB. After surgery patients will follow the norma

Trial Details

NCT ID

NCT05423210

Phase

EARLY_PHASE1

Sponsor

Stony Brook University

Status

RECRUITING

Cancer Type

Glioblastoma (GBM) Brain Cancer

Interventions

• Atezolizumab + FSRT radiation

Locations (sample)

• Stony Brook, New York, United States|40.92565,-73.14094

Key Eligibility Criteria

• Diagnosis of glioblastoma multiforme WHO Grade IV
• The patient is a surgical candidate, with the surgical intent for a \> 80% resection of the lesion
• Negative pregnancy test
• ECOG status \<= 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →